Related references
Note: Only part of the references are listed.The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra et al.
JOURNAL OF HEPATOLOGY (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
Future trends in the treatment of non-alcoholic steatohepatitis
Stefano Fiorucci et al.
PHARMACOLOGICAL RESEARCH (2018)
Viewpoint: A Contributory Role of Shell Ginger (Alpinia zerumbet) for Human Longevity in Okinawa, Japan?
Rolf Teschke et al.
NUTRIENTS (2018)
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
Melissa Palmer et al.
BMC PHARMACOLOGY & TOXICOLOGY (2018)
Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin
Yuji Ogawa et al.
SCIENTIFIC REPORTS (2018)
Optimal nutrition and the ever-changing dietary landscape: a conference report
A. Shao et al.
EUROPEAN JOURNAL OF NUTRITION (2017)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial
Melanie Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Targeting the gut-liver axis in liver disease
Reiner Wiest et al.
JOURNAL OF HEPATOLOGY (2017)
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
Hannes Hagstrom et al.
JOURNAL OF HEPATOLOGY (2017)
Treatment of NAFLD with diet, physical activity and exercise
Manuel Romero-Gómez et al.
JOURNAL OF HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates
Pi-Xiao Wang et al.
NATURE MEDICINE (2017)
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Mei Zhou et al.
NATURE COMMUNICATIONS (2017)
Fibroblast growth factor 21, assisted by elevated glucose, activates paraventricular nucleus NUCB2/Nesfatin-1 neurons to produce satiety under fed states
Putra Santoso et al.
SCIENTIFIC REPORTS (2017)
Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease
Frank J. Gonzalez et al.
DIGESTIVE DISEASES (2017)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Melanie Thompson et al.
AIDS (2016)
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
Shun Ishibashi et al.
ATHEROSCLEROSIS (2016)
Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman et al.
CONTEMPORARY CLINICAL TRIALS (2016)
Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers
R. Pencek et al.
DIABETES OBESITY & METABOLISM (2016)
Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease
Rolf Teschke et al.
DRUG SAFETY (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury
Jana C. Mossanen et al.
HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Elena Buzzetti et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
The role of the gut microbiota in NAFLD
Christopher Leung et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Role of Cholesterol in the Pathogenesis of NASH
George N. Ioannou
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2016)
Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
Christopher L. Bowlus
HEPATIC MEDICINE-EVIDENCE AND RESEARCH (2016)
Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
Nobuyuki Itoh et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis
Jonathan Y. Xia et al.
CELL METABOLISM (2015)
Mediterranean diet and non-alcoholic fatty liver disease. The need of extended and comprehensive interventions
Francesca M. Trovato et al.
CLINICAL NUTRITION (2015)
Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial
Kate Hallsworth et al.
CLINICAL SCIENCE (2015)
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Steven A. Kliewer et al.
DIGESTIVE DISEASES (2015)
Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield et al.
GASTROENTEROLOGY (2015)
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
Eduardo Vilar-Gomez et al.
GASTROENTEROLOGY (2015)
Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
Robert J. Wong et al.
GASTROENTEROLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Nonalcoholic Fatty Liver Disease A Systematic Review
Mary E. Rinella
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Sumio Watanabe et al.
JOURNAL OF GASTROENTEROLOGY (2015)
NAFLD: A multisystem disease
Christopher D. Byrne et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
Michal Pawlak et al.
JOURNAL OF HEPATOLOGY (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice
R. H. Elbekai et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2015)
The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
Fernando J. Barreyro et al.
LIVER INTERNATIONAL (2015)
Prevention of Diabetes With Mediterranean Diets A Subgroup Analysis of a Randomized Trial
Jordi Salas-Salvado et al.
ANNALS OF INTERNAL MEDICINE (2014)
Mediterranean Diet and Cardiovascular Risk Factors: A Systematic Review
Giuseppe Grosso et al.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2014)
Roles for Chemokines in Liver Disease
Fabio Marra et al.
GASTROENTEROLOGY (2014)
Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia
Martha J. Kelly et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Bile acid receptors as targets for drug development
Frank G. Schaap et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development
Chun-Meng Jiang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors
Paola Dongiovanni et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Hannele Yki-Jarvinen
LANCET DIABETES & ENDOCRINOLOGY (2014)
Several herbal compounds in Okinawa plants directly inhibit the oncogenic/aging kinase PAK1
Binh Cao Quan Nguyen et al.
DRUG DISCOVERIES AND THERAPEUTICS (2014)
Significant Longevity-Extending Effects of Alpinia zerumbet Leaf Extract on the Life Span of Caenorhabditis elegans
Atul Upadhyay et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2013)
Selective peroxisome proliferator-activated receptora modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
Jean-Charles Fruchart
CARDIOVASCULAR DIABETOLOGY (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Lazar A. Bojic et al.
CURRENT OPINION IN LIPIDOLOGY (2013)
Hepatoprotective Effects of the Dual Peroxisome Proliferator-Activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Bart Staels et al.
HEPATOLOGY (2013)
Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan
Takuya Kitamoto et al.
HUMAN GENETICS (2013)
Brown seaweed fucoidan: Biological activity and apoptosis, growth signaling mechanism in cancer
Kalimuthu Senthilkumar et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2013)
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Giovanni Musso et al.
PROGRESS IN LIPID RESEARCH (2013)
Of mice and men: The benefits of caloric restriction, exercise, and mimetics
Evi M. Mercken et al.
AGEING RESEARCH REVIEWS (2012)
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
E. Boettcher et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
James Mu et al.
DIABETES (2012)
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
Kenneth Cusi
GASTROENTEROLOGY (2012)
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Naga Chalasani et al.
GASTROENTEROLOGY (2012)
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
Romina Lomonaco et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Geoffrey Porez et al.
JOURNAL OF LIPID RESEARCH (2012)
Pathologic Criteria for Nonalcoholic Steatohepatitis: Interprotocol Agreement and Ability to Predict Liver-Related Mortality
Zobair M. Younossi et al.
HEPATOLOGY (2011)
Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Eric A. Klein et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
The role of thiazolidinediones in non-alcoholic steatohepatitis - A systematic review and meta analysis
Suzanne E. Mahady et al.
JOURNAL OF HEPATOLOGY (2011)
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Giovanni Musso et al.
HEPATOLOGY (2010)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis
Quentin M. Anstee et al.
JOURNAL OF HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pan-Caspase Inhibitor VX-166 Reduces Fibrosis in an Animal Model of Nonalcoholic Steatohepatitis
Rafal P. Witek et al.
HEPATOLOGY (2009)
The Okinawan Diet: Health Implications of a Low-Calorie, Nutrient-Dense, Antioxidant-Rich Dietary Pattern Low in Glycemic Load
D. Craig Willcox et al.
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION (2009)
Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice
Xinle Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
Winston Dunn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance
Justin I. Odegaard et al.
CELL METABOLISM (2008)
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach
Stefano Bellentani et al.
HEPATOLOGY (2008)
Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes
Myoung Sook Han et al.
JOURNAL OF LIPID RESEARCH (2008)
Thyroid disease and the heart
Irwin Klein et al.
CIRCULATION (2007)
Bile acid transporters: Structure, function, regulation and pathophysiological implications
Waddah A. Alrefai et al.
PHARMACEUTICAL RESEARCH (2007)
Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor Isoforms determines metabolic activity of FGF19 and FGF21
Hiroshi Kurosu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention - Systematic review and meta-analysis
Goran Bjelakovic et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
First-in-class pan caspase inhibitor developed for the treatment of liver disease
SD Linton et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
The natural history of nonalcoholic fatty liver disease: A population-based cohort study
LA Adams et al.
GASTROENTEROLOGY (2005)
Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality
ER Miller et al.
ANNALS OF INTERNAL MEDICINE (2005)
The ASK1-MAP kinase cascades in mammalian stress response
J Matsukawa et al.
JOURNAL OF BIOCHEMISTRY (2004)
Thiazolidinedione use, fluid retention, and congestive heart failure
RW Nesto et al.
DIABETES CARE (2004)
Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials
RP Mensink et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2003)
A mouse model of hepatocellular carcinoma - Ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice
K Nicholes et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Medical progress - Nonalcoholic fatty liver disease
P Angulo
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Mechanism of thyroid-hormone regulated expression of the SERCA genes in skeletal muscle: Implications for thermogenesis
WS Simonides et al.
BIOSCIENCE REPORTS (2001)
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
AJ Sanyal et al.
GASTROENTEROLOGY (2001)
Share Paper
